Generex Biotechnology Corporation (GNBT-NASDAQ) |
|
Generex Biotechnology
CEOCFO Current Issue |
This is a printer friendly page! Generex Biotechnology
is the First Company to Market Non-Injectible Insulin Receives Regulatory Approval
in South America Pharmaceutical Anna Gluskin BIO: Among todays competing technologies, only
Oral-lyn, an insulin spray to treatment diabetes, meets all those tests. After 10
years of development, Oral-lyn is ready for market and is set to produce enormous
revenue growth for the company. Generex is little known outside a small community of
investors focused on drug delivery and diabetes treatment. The commercial entry of
Oral-lyn in CEOCFOinterviews: Ms. Gluskin, what was your
vision for Generex and how has it played out? Ms. Gluskin: The idea, when the company
was organized, was to be involved in drug delivery and drug discovery, working with
medications that have been on the market for a long time and have been proven to be
safe. CEOCFOinterviews: What is the need for new
drug delivery systems? Ms. Gluskin: The need for new drug
delivery systems is that the existing drug delivery does not achieve proper absorption
value. The patients are not compliant. When new diseases are happening, people are now
living longer, because they are able to combat their diseases with existing drugs, but can
have greater success because of the new delivery systems. CEOCFOinterviews: Will you tell us what you
are doing at Generex? Ms. Gluskin: We are working with a large
molecule and a protein, which means it is by injection only and we have developed an oral
insulin spray, which absorbs within ten minutes. We have also developed other products
based on the same technology, which include a platform in aerosol spray, medicinal gum,
and a number of other areas. CEOCFOinterviews: Lets talk about the
insulin spray; would people be more likely to take insulin rather than some of the other
medications in use if insulin did not have to be injected? Ms. Gluskin: Yes, that is the idea. All
the other drugs that have been given so far have only been given instead of insulin
because people refuse to inject themselves. They are all measured. They are only delaying
the use of insulin, but by delaying it, they are causing the patients to develop a number
of serious complications such as heart disease, blindness and amputations of lower
extremities. CEOCFOinterviews: Where are you in getting
this product to market? Ms. Gluskin: We are very pleased to have
made the announcement that we have received approval to market Oral-lyn in CEOCFOinterviews: Why did you choose Mr.: CEOCFOinterviews: You mentioned that it does
not go into the lungs, what is the significance of that? Ms. Gluskin: Competitive products have
been bringing it into the lung, because when insulin was discovered in CEOCFOinterviews: Tell us about the
manufacturing process. Ms. Gluskin: We will be doing the entire
manufacturing, but will license marketing and distribution to other companies that are
going to take it to market. CEOCFOinterviews: Will you tell us about the
Australian patent and some of the other areas of Generex? Ms. Gluskin: Generex has acquired a
company called Antigen Express. It is a company in CEOCFOinterviews: How are you funding all of
the areas in which you are working? Ms. Gluskin: It is expensive and it is
difficult to fund privately, so the company is public, money from public markets. Now, we
are hoping that the next move for funding and development is going to come from marketing
of our licenses. Money from these licenses go directly to the bottom-line. By selling the
territorial licenses instead of licensing the whole, we will be able to generate
funds. CEOCFOinterviews: Do you see partnerships on
the horizon or strictly the licensing? Ms. Gluskin: We have a number of big
Pharmas that are interested in dealing with us. We believe that by staying involved longer
and purchasing the patents that we have and taking the product to market, that we will
eventually make Generex grow as a company and as a stock. CEOCFOinterviews: What should potential
investors know that maybe they do not realize when they first look at the company? Ms. Gluskin: People are always impressed
by partnerships with big Pharma; I would like to remind them that they should check the
record of big Pharma, particularly companies like Pfizer Inc. (NYSE: PFE) and Merck &
Co. (NYSE: MRK), because they brought new products to market and because of safety issues,
they had to take them off the market. What we have is a simple and effective system and
safety, which is a paramount issue, taken care of and has been proven for forty to fifty
years. We know that many drugs hurt the stomach if they get there to fast, so our motto is
quality of life. CEOCFOinterviews: In closing, I noticed you
mentioned that innovation and opportunity as a formula for success, and it sounds like you
have both! Ms. Gluskin: Absolutely, and we are
still not out there enough, and people need to know us. We believe that with the news of
our registration and good support and applications, that we will be able to get the word
out. |
To view Releases highlight & left click on the company name!
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.
.